<SEC-DOCUMENT>0001213900-19-005717-index.html : 20190403
<SEC-HEADER>0001213900-19-005717.hdr.sgml : 20190403
<ACCEPTANCE-DATETIME>20190403163217
ACCESSION NUMBER:		0001213900-19-005717
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20190401
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190403
DATE AS OF CHANGE:		20190403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		19729424

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k040119_citiupharma.htm
<TEXT>
Document 1 - file: f8k040119_citiupharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>f8k040119ex4-1_citiupharma.htm
<DESCRIPTION>COMMON STOCK PURCHASE WARRANT
<TEXT>
Document 2 - file: f8k040119ex4-1_citiupharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>f8k040119ex4-2_citiupharma.htm
<DESCRIPTION>PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT
<TEXT>
Document 3 - file: f8k040119ex4-2_citiupharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>f8k040119ex5-1_citiupharma.htm
<DESCRIPTION>OPINION OF WYRICK ROBBINS YATES & PONTON LLP
<TEXT>
Document 4 - file: f8k040119ex5-1_citiupharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>f8k040119ex10-1_citiupharma.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT
<TEXT>
Document 5 - file: f8k040119ex10-1_citiupharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>f8k040119ex10-2_citiupharma.htm
<DESCRIPTION>LETTER AGREEMENT
<TEXT>
Document 6 - file: f8k040119ex10-2_citiupharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>f8k040119ex99-1_citiupharma.htm
<DESCRIPTION>CITIUS ANNOUNCES $5.3 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET
<TEXT>
Document 7 - file: f8k040119ex99-1_citiupharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 8 - file: ex10-2_001.jpg

</DOCUMENT>
</SEC-DOCUMENT>